Thomas M. Suter

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

A. Goldhirsch, C. Criscitiello, G. Curigliano, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

J. Baselga, T. Suter, D. Lenihan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

R. Coombes, M. Climent, U. Dafni, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.

T. Suter, C. Barton, N. Cook-Bruns, 2004, Breast.

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

E. D. de Vries, T. Suter, J. Gietema, 2007, European journal of cancer.

Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.

N. Harbeck, T. Suter, M. Ewer, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013, The Lancet.